Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases

Neurobiology of Disease

Volumn 58, Issue , 2013, Pages 183-190

  Mamais, Adamantios ^a,b   Raja, Meera ^a,b   Manzoni, Claudia ^b   Dihanich, Sybille ^b   Lees, Andrew ^a,b   Moore, Darren ^c   Lewis, Patrick A ^b,d   Bandopadhyay, Rina ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c EPFL   (Switzerland)

^d UNIVERSITY OF READING   (United Kingdom)

Author keywords

Synuclein; Differential solubility; G2019S; Immunohistochemistry; LRRK2

Indexed keywords

ALPHA SYNUCLEIN; LEUCINE RICH REPEAT KINASE 2;

ADRENAL MEDULLA; AGED; ARTICLE; AUTOPSY; BASAL GANGLION; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DOPAMINERGIC NERVE CELL; FEMALE; FRONTAL CORTEX; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; LEWY BODY; LIMBIC CORTEX; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; SCORING SYSTEM; SOLUBILITY;

Α-SYNUCLEIN; DIFFERENTIAL SOLUBILITY; G2019S; IMMUNOHISTOCHEMISTRY; LRRK2;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; BRAIN; FEMALE; GENE EXPRESSION REGULATION; GLYCINE; HUMANS; LEWY BODIES; MALE; PARKINSON DISEASE; POSTMORTEM CHANGES; PROTEIN-SERINE-THREONINE KINASES; SERINE;

EID: 84879573207     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.05.017     Document Type: Article

References (61)

1. Anderson J.P., et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 2006, 281:29739-29752.
2. Arrasate M., et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004, 431:805-810.
3. Berwick D.C., Harvey K. LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6. Hum. Mol. Genet. 2012, 21:4966-4979.
4. Booij J., Knol R.J. SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease. Parkinsonism Relat. Disord. 2007, 13:S425-S428.
5. Botta-Orfila T., et al. Age at onset in LRRK2-associated PD is modified by SNCA variants. J. Mol. Neurosci. 2012.
6. Braak H., et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
7. Campbell B.C., et al. Accumulation of insoluble alpha-synuclein in dementia with Lewy bodies. Neurobiol. Dis. 2000, 7:192-200.
8. Campbell B.C., et al. The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J. Neurochem. 2001, 76:87-96.
9. Cookson M.R. Alpha-synuclein and neuronal cell death. Mol. Neurodegener. 2009, 4:9.
10. Cookson M.R., et al. Genetic neuropathology of Parkinson's disease. Int. J. Clin. Exp. Pathol. 2008, 1:217-231.
11. Cremades N., et al. Direct observation of the interconversion of normal and toxic forms of alpha-synuclein. Cell 2012, 149:1048-1059.
12. Daher J.P., et al. Neurodegenerative phenotypes in an A53T alpha-synuclein transgenic mouse model are independent of LRRK2. Hum. Mol. Genet. 2012, 21:2420-2431.
13. Devine M.J., et al. Pathogenic LRRK2 mutations do not alter gene expression in cell model systems or human brain tissue. PLoS One 2011, 6:e22489.
14. Fujiwara H., et al. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4:160-164.
15. Galvin J.E., et al. Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. Am. J. Pathol. 2000, 157(2):361-368.
16. Gandhi P.N., et al. The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J. Neurosci. Res. 2008, 86:1711-1720.
17. Gilks W.P., et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005, 365:415-416.
18. Gomez A., Ferrer I. Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment. Acta Neuropathol. 2010, 120:155-167.
19. Greggio E., Cookson M.R. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 2009, 1.
20. Greggio E., et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 2006, 23:329-341.
21. Guerreiro P.S., et al. LRRK2 interactions with alpha-synuclein in Parkinson's disease brains and in cell models. J. Mol. Med. 2012, 91:513-522. (Berl).
22. Healy D.G., et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson' disease: a case-control study. Lancet Neurol. 2008, 7:583-590.
23. Herzig M.C., et al. High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain. PLoS One 2012, 7:e36581.
24. Imai Y., et al. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 2008, 27:2432-2443.
25. Jaleel M., et al. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J. 2007, 405:307-317.
26. Johansen K.K., et al. Metabolomic profiling in LRRK2-related Parkinson's disease. PLoS One 2009, 4:e7551.
27. Johansen K.K., et al. Subclinical signs in LRRK2 mutation carriers. Parkinsonism Relat. Disord. 2011, 17:528-532.
28. Kingsbury A.E., et al. Brain stem pathology in Parkinson's disease: an evaluation of the Braak staging model. Mov. Disord. 2010, 25:2508-2515.
29. Kondo K., et al. Alpha-synuclein aggregation and transmission are enhanced by leucine-rich repeat kinase 2 in human neuroblastoma SH-SY5Y cells. Biol. Pharm. Bull. 2011, 34:1078-1083.
30. Lee C.R., Tepper J.M. Basal ganglia control of substantia nigra dopaminergic neurons. J. Neural Transm. Suppl. 2009, 71-90.
31. Li J.Y., et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 2008, 14:501-503.
32. Lin X., et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 2009, 64:807-827.
33. Martin I., et al. The impact of genetic research on our understanding of Parkinson's disease. Prog. Brain Res. 2010, 183:21-41.
34. Mata I.F., et al. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 2006, 29:286-293.
35. McKeith I.G., et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65:1863-1872.
36. Miller D.W., et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 2004, 62:1835-1838.
37. Muntane G., et al. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies. Neuroscience 2008, 152:913-923.
38. Nalls M.A., et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011, 377:641-649.
39. Neumann M., et al. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J. Clin. Invest. 2002, 110:1429-1439.
40. Paisan-Ruiz C., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004, 44:595-600.
41. Pchelina S.N., et al. Reduced content of alpha-synuclein in peripheral blood leukocytes of patients with LRRK2-associated Parkinson's disease. Bull. Exp. Biol. Med. 2011, 150:679-681.
42. Poulopoulos M., et al. Clinical and pathological characteristics of LRRK2 G2019S patients with PD. J. Mol. Neurosci. 2012, 47:139-143.
43. Qing H., et al. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem. Biophys. Res. Commun. 2009, 387:149-152.
44. Ross O.A., et al. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol. 2011, 10:898-908.
45. Sancho R.M., et al. Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways. Hum. Mol. Genet. 2009, 18:3955-3968.
46. Schulz-Schaeffer W.J. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol. 2010, 120:131-143.
47. Sharma S., et al. LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study. Neuropathol. Appl. Neurobiol. 2011, 37:777-790.
48. Smith W.W., et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18676-18681.
49. Smith W.W., et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 2006, 9:1231-1233.
50. Spillantini M.G., et al. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
51. Stafa K., et al. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet. 2012, 8:e1002526.
52. Tan E.K., Skipper L.M. Pathogenic mutations in Parkinson disease. Hum. Mutat. 2007, 28:641-653.
53. Tong Y., et al. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14622-14627.
54. Trancikova A., et al. Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations. PLoS One 2012, 7:e47784.
55. Vekrellis K., et al. Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol. 2011, 10:1015-1025.
56. Wakamatsu M., et al. Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein. J. Neurosci. Res. 2007, 85:1819-1825.
57. West A.B., et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:16842-16847.
58. Westerlund M., et al. Lrrk2 and alpha-synuclein are co-regulated in rodent striatum. Mol. Cell. Neurosci. 2008, 39:586-591.
59. Wider C., et al. Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation. Neurodegener. Dis. 2010, 7:175-179.
60. Zhou J., et al. Changes in the solubility and phosphorylation of alpha-synuclein over the course of Parkinson's disease. Acta Neuropathol. 2011, 121:695-704.
61. Zimprich A., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.